Add time:09/05/2019         Source:sciencedirect.com

It has long been recognized that monoamine oxidase (MAO) inhibitors have a role in the management of Parkinson's disease (PD). The MAO‐B inhibitor Rasagiline (cas 136236-51-6) has neuroprotective effects in animal models, mediated partly by its antiapoptotic activity. Rasagiline has been shown to be effective as monotherapy for early PD and as an adjunct to dopaminergic therapy. Clinical trials have also shown putative disease-modifying effects, though rasagiline's potential to alter the long-term course of PD remains controversial. Given the demonstrated benefits of rasagiline, along with its safety and tolerability profile, it has an important role to play in PD therapy.

We also recommend Trading Suppliers and Manufacturers of Rasagiline (cas 136236-51-6). Pls Click Website Link as below: cas 136236-51-6 suppliers